Table 3.
Validation Statistics for MCF7 Trained Candidate High Performance Classifiers
| MIE Name | Exemplar Chemical | Exemplar Rank | Exemplar Percent Rank | KS Test Chemicals | KS Test p-value |
|---|---|---|---|---|---|
| ADRA2A (+) | Epinephrine | 2826 / 11,666 | 0.76 | 2 | 0.09 |
| ALOX5 (−) | MK 886 | 4291.5 / 11,672 | 0.63 | 3 | 0.87 |
| AR (+) | 17-Methyltestosterone | 10,226 / 11,665 | 0.12 | 10 | 0.02 |
| DRD2 (−) | Haloperidol | 3042 / 11,623 | 0.74 | 8 | 0.09 |
| ESR-1/2 (−) | Tamoxifen | 26 / 11,661 | 1.00 | 5 | 0.10 |
| ESR-1/2 (+) | 17beta-Estradiol | 517 / 11,604 | 0.96 | 22 | 0.03 |
| FLT1/KDR (−) | Erlotinib | 1125 / 11,620 | 0.90 | 23 | 0.34 |
| HDAC (−) | MS-275 | 357 / 11,589 | 0.97 | 13 | 0.00 |
| HMGCR (−) | Mevastatin | 922 / 11,672 | 0.92 | 3 | 0.00 |
| HRH1 (−) | Astemizole | 8838 / 11,630 | 0.24 | 14 | 0.61 |
| JAK2 (−) | NA | NA | NA | 4 | 0.34 |
| KCNH2 (−) | Haloperidol | 3438 / 11,522 | 0.70 | 22 | 0.01 |
| MAPK14 (−) | NA | NA | NA | 13 | 0.87 |
| MET (−) | Cabozantinib | 5357 / 11,626 | 0.54 | 3 | 0.56 |
| MTOR/PI3K (−) | Everolimus | 3 / 11,572 | 1.00 | 11 | 0.01 |
| NR3C1 (+) | Clocortolone pivalate | 322 / 11,639 | 0.97 | 19 | 0.02 |
| PTGS-1/2 (−) | Flurbiprofen | 4782 / 11,556 | 0.59 | 20 | 0.41 |
| SLC22A6 (−) | Methotrexate | 8663 / 11,671 | 0.26 | 18 | 0.52 |
| TOP2A (−) | Doxorubicin | 16 / 11,652 | 1.00 | 5 | 0.02 |
| TUB (−) | Vinblastine | 27 / 11,636 | 1.00 | 6 | 0.00 |
Bolded entries are the nine confirmed high performance classifiers as determined by an exemplar percent rank ≥0.90